Back to Search
Start Over
Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches
- Source :
- Proteomes, Vol 9, Iss 42, p 42 (2021), Proteomes, Volume 9, Issue 4
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual patients. However, constant refinements are needed, and the inclusion of significant measurements, based on the various omics approaches that are currently available to researchers/clinicians, have the potential to increase overall accuracy with respect to patient management. Using both nontargeted (label-free mass spectrometry) and targeted (multiplex immunoassays) proteomics, a range of proteins were found to be significantly changed in AML patients with different genetic backgrounds. The inclusion of validated proteomic biomarker panels could be an important factor in the prognostic classification of AML patients. The ability to measure both cellular and secreted analytes, at diagnosis and during the course of treatment, has advantages in identifying transforming biological mechanisms in patients, assisting important clinical management decisions.
- Subjects :
- Oncology
medicine.medical_specialty
Myeloid
BONE-MARROW
3122 Cancers
Clinical Biochemistry
acute myeloid leukemia
Proteomics
Biochemistry
Microbiology
proteomiikka
Article
CYTOKINE LEVELS
03 medical and health sciences
0302 clinical medicine
proteomics
POOR-PROGNOSIS
Structural Biology
Internal medicine
hemic and lymphatic diseases
PROGNOSTIC-SIGNIFICANCE
medicine
BREAST-CANCER
Multiplex
In patient
immunoassay
LACTIC-DEHYDROGENASE
Molecular Biology
030304 developmental biology
mass spectrometry
DRUG-RESISTANCE
0303 health sciences
318 Medical biotechnology
THERAPEUTIC TARGET
business.industry
DISEASE PROGRESSION
Myeloid leukemia
biomarkers
Omics
QR1-502
3. Good health
medicine.anatomical_structure
biomarkkeri
030220 oncology & carcinogenesis
Akuutti myelooinen leukemia
Biomarker (medicine)
Identification (biology)
business
STEM-CELLS
Subjects
Details
- Language :
- English
- ISSN :
- 22277382
- Volume :
- 9
- Issue :
- 42
- Database :
- OpenAIRE
- Journal :
- Proteomes
- Accession number :
- edsair.doi.dedup.....ce5372e68f542d12fbba6b3c3c61087a